JD Bioscience Gains FDA Approval for Phase 2a Clinical Trials on Fatty Liver Drug

The Gwangju Institute of Science and Technology (GIST) noted that the new drug candidate ‘GM-60106’, developed by JD BioScience, received global clinical Phase IIa trial plan approval from the US FDA.